ArticleLifetime data analysis2026
No cure for cure models: killed by competing risks.
Article in Lifetime data analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cure models have become increasingly popular over the last couple of decades. An appealing element of cure models is the idea that part of the population is immune to the event of interest. We argue that, in medical applications, the use of cure models is limited. Thus, true cure cannot exist if the event of interest includes death, as death is inevitable, and if death is excluded then competing risks must be accounted for. In this case, we find it more natural to model the cumulative incidence of both the event of interest and competing events over time, avoiding unreliable estimates at infinity and using observed data. Further, we point out two more technical difficulties with cure models arising, first, from the fact that cure models rely on identifying plateaus in survival curves at the tail, where data may be sparse and unreliable and, second, the mixture cure model faces issues with practical identifiability of covariate effects in the incidence model (probability of cure), especially alongside proportional hazards assumptions in the latency model (survival model, conditionally on not being cured). We also comment on hybrid extensions of the classical single event cure model that allow for both competing risks and a cured fraction. We support our arguments with real and simulated data. Full data and code are available online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.